The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
Open accessAbstract
BACKGROUND: Long-term trends in excess risk of death and cardiovascular outcomes have not been extensively studied in persons with type 1 diabetes or type 2 diabetes. METHODS: We included patients registered in the Swedish National Diabetes Register from 1998 through 2012 and followed them through 2014. Trends in deaths and cardiovascular events were estimated with Cox regression and standardized incidence rates. For each patient, controls who were matched for age, sex, and county were randomly selected from the general population. RESULTS: Among patients with type 1 diabetes, absolute changes during the study period in the incidence rates of sentinel outcomes per 10,000 person-years were as follows: death from any cause, -31.4 (95% confidence interval [CI], -56.1 to -6.7); death from cardiovascular disease, -26.0 (95% CI, -42.6 to -9.4); death from coronary heart disease, -21.7 (95% CI, -37.1 to -6.4); and hospitalization for cardiovascular disease, -45.7 (95% CI, -71.4 to -20.1). Absolute changes per 10,000 person-years among patients with type 2 diabetes were as follows: death from any cause, -69.6 (95% CI, -95.9 to -43.2); death from cardiovascular disease, -110.0 (95% CI, -128.9 to -91.1); death from coronary heart disease, -91.9 (95% CI, -108.9 to -75.0); and hospitalization for cardiovascular disease, -203.6 (95% CI, -230.9 to -176.3). Patients with type 1 diabetes had roughly 40% greater reduction in cardiovascular outcomes than controls, and patients with type 2 diabetes had roughly 20% greater reduction than controls. Reductions in fatal outcomes were similar in patients with type 1 diabetes and controls, whereas patients with type 2 diabetes had smaller reductions in fatal outcomes than controls. CONCLUSIONS: In Sweden from 1998 through 2014, mortality and the incidence of cardiovascular outcomes declined substantially among persons with diabetes, although fatal outcomes declined less among those with type 2 diabetes than among controls. (Funded by the Swedish Association of Local Authorities and Regions and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Atherosclerotic cardiovascular disease (ASCVD) broadly refers to a history of acute coronary syndrome, myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral artery disease (PAD) including aortic aneurysm and is the leading cause of morbidity and mortality in people with diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ASCVD broadly refers to a history of acute coronary syndrome, myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, or peripheral artery disease (PAD) including aortic aneurysm and is the leading cause of morbidity and mortality in people with diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Under the current paradigm of comprehensive risk factor modification, cardiovascular morbidity and mortality have notably decreased in people with both type 1 and type 2 diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Under the current paradigm of comprehensive risk factor modification, cardiovascular morbidity and mortality have notably decreased in people with both type 1 and type 2 diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [1]
In the citing paper
“T2DM is common among patients with ASCVD or at the highest risk of CVD.The converse is also true: ASCVD is common in patients with T2DM.148”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [148]
In the citing paper
“Diabetes is a well-established risk factor for ischaemic heart disease (IHD), and CAD accounts for 40-80% of deaths in patients with T2DM.148,359,381”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [148]
In the citing paper
“These results were consistent across subgroups including those with and without diabetes or CKD.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“The primary outcome of worsening HF or CVD death was significantly reduced, 16.3% versus 21.2% for dapagliflozin compared with placebo (HR, 0.74; 95% CI, 0.65–0.85).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“Patients with T2DM are at high risk for ASCVD and HF compared with nondiabetic individuals (50,53).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“DAPA-HF was the first clinical trial of an SGLT2 inhibitor to assess HF events as the primary outcome and to include participants with and without diabetes (50).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
Whiting, D. R., Guariguata, L., Weil, C., & Shaw, J. E. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.029 · Cited by 4,018
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Strona, V. I., Gorb, Y. G., & Komir, I. (2018) · Актуальні проблеми сучасної медицини Вісник Української медичної стоматологічної академії · doi:10.31718/2077-1096.18.4.59 · Cited by 3
Heart Failure and Diabetes: Perspective of a Dangerous Association
Favaloro, L. E., Ratto, R., & Musso, C. (2021) · Current Hypertension Reviews · doi:10.2174/1573402117666210406111927 · Cited by 3
Copetti, M., Biancalana, E., Fontana, A., Parolini, F., Garofolo, M., Lamacchia, O., Cosmo, S. D., Trischitta, V., & Solini, A. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01746-2 · Cited by 3
Hohendorff, J., Kwiatkowska, M., Pisarczyk-Wiza, D., Ludwig‐Słomczyńska, A. H., Milcarek, M., Kapusta, P., Zapała, B., Kieć‐Wilk, B., Trznadel-Morawska, I., Szopa, M., et al. (2021) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16143 · Cited by 3
Kumaravelrajan, R., Thirumaran, M., Sangavi, T., & Suba, V. (2022) · INDIAN DRUGS · doi:10.53879/id.58.12.12701 · Cited by 3
Hoffmann, A. P., & Honigberg, M. C. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01024-8 · Cited by 3
Bhandu, P., Verma, H., Singh, M., Kumar, M., Narendra, G., Choudhary, S., Singh, P. K., & Silakari, O. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133825 · Cited by 3
Rydberg, M., Zimmerman, M., Gottsäter, A., Åkesson, A., Eeg‐Olofsson, K., Arner, M., & Dahlin, L. B. (2023) · Plastic & Reconstructive Surgery Global Open · doi:10.1097/gox.0000000000005037 · Cited by 3
Inkeri, J., Harjutsalo, V., Martola, J., Putaala, J., Groop, P., Gordin, D., Thorn, L. M., the FinnDiane Study Group, Koivula, S., Uggeldahl, T., et al. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02211-y · Cited by 3
Mayyas, F., Ibrahim, K. S., Ibdah, R., Al-Kasasbeh, A., Ababneh, M. J., Ababneh, A., AL-JARRAH, M. I., & Rawashdeh, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37777 · Cited by 3
Use of Cardioprotective Adjuncts in Type 1 Diabetes
Greenfield, J. R., Frampton, R., Millard, K., & SNAITH, J. R. (2025) · Diabetes Therapy · doi:10.1007/s13300-024-01687-3 · Cited by 3
Diagnostics of impaired carbon metabolism in patients with ischemic heart disease.
Mankovskyi, G. B. (2018) · Medicni perspektivi · doi:10.26641/2307-0404.2018.2.133698 · Cited by 3
Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure
Imprialos, K. P., Stavropoulos, K., & Papademetriou, V. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.06.004 · Cited by 3
Nicolau, J. C., Brieger, D. B., Owen, R., Furtado, R. H. M., Goodman, S. G., Cohen, M. G., Simon, T., Westermann, D., Granger, C. B., Grieve, R., et al. (2020) · Clinical Cardiology · doi:10.1002/clc.23476 · Cited by 3
Diabetic Control Agents and Their Impact on Cardiac Surgery Patients: A Clinical Overview
O’Neill, P., Leung, M. S. T., Visser, R. A. B., & Harky, A. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420963688 · Cited by 3
Canney, M., Birks, P., Shao, S., Parfrey, P. S., Djurdjev, O., & Levin, A. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2020.12.022 · Cited by 3
Quality of Diabetes Care in the USA
Alencherry, B., & Bruemmer, D. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01503-5 · Cited by 3
Sudevan, R., Raj, M., Vasudevan, D., Arun, C., Thachathodiyl, R., Vijayakumar, M., Abdullakutty, J., Thomas, P., George, V., & Kabali, C. (2021) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_532_20 · Cited by 3
Planas, A., Simó‐Servat, O., Hernández, C., Ortiz-Zúñiga, Á., Marsal, J. R., Herance, J. R., González, I. F., & Simó, R. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121344 · Cited by 3
Integrating traditional Chinese medicine and western medicine for cardiovascular disease
Xiang, Y. (2022) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0388 · Cited by 3
Kanumilli, N., Butler, J., Makrilakis, K., Rydén, L., Vallis, M., Wanner, C., Zieroth, S. R., Alhussein, A., & CHENG, A. Y. Y. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01418-0 · Cited by 3
Cormican, D. S., Jayaraman, A. L., Sheu, R. D., Peterson, C., Narasimhan, S., Shaefi, S., Nuñez-Gil, I. J., & Ramakrishna, H. (2018) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2018.09.019 · Cited by 3
Kjær, L. K., Grand, M. K., Siersma, V., Broedbaek, K., Jørgensen, A., Olivarius, N. D. F., & Poulsen, H. E. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.12.004 · Cited by 3
Agha, A. M., & Ballantyne, C. M. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_4 · Cited by 3
Nationale Diabetes Registratie
Serné, E. H., Mourits, P., & van Strien, M. (2020) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-020-0131-2 · Cited by 3
Lifestyle and CV Risk in Patients With Diabetes
Connelly, K. A., Gandhi, S., & Horton, E. S. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.028 · Cited by 3
Improving Outcomes in Patients With Diabetes Mellitus
Aguilar, D. A. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.011971 · Cited by 3
From Global Thinking to Local Action: The Planetary Diet as Chronic Disease Prevention
Selvik, H. A., & Fullilove, R. E. (2020) · Public Health Reports · doi:10.1177/0033354920935070 · Cited by 3
Siddiqui, K., & Maddaloni, E. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.816481 · Cited by 3
Li, M., Pan, J., Wang, J.-H., Hu, Z.-L., Zhao, J., & Wei, H. (2023) · Technology and Health Care · doi:10.3233/thc-230243 · Cited by 2
Clinical Impact of Glucose Levels on Patient Outcome after Transcatheter Aortic Valve Replacement
Khadija, H. A., Alnees, M., Gandelman, G., Awwad, M., Schiller, T., Hamdan, Y., Ayyad, O., Kirzhner, A., Sella, G., Kashquosh, Y., et al. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25336 · Cited by 3
Malas, K., Kazmi, S., Kang, Y. M., & McGuire, D. K. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2504702 · Cited by 3
Self-citationBae, J. H., Lee, M. J., Kim, S. H., Kim, J. Y., Khang, A. R., Kang, Y. H., & Yi, D. (2025) · PLoS ONE · doi:10.1371/journal.pone.0327058 · Cited by 2
Thylefors, J., Gershater, M. A., Mangrio, E., & Zdravkovic, S. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1583817 · Cited by 2
Dong, Y., Chang, C., Wu, L., & Toh, S. (2025) · Clinical and Translational Science · doi:10.1111/cts.70319 · Cited by 2
Yu, M. G., Shah, H., JANGOLLA, S. V. T., Gauthier, J., VIEBRANZ, E. R., Wu, I., Chokshi, T. J., Park, K., Li, Q., Fickweiler, W., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06521-4 · Cited by 3
Lavens, A., Block, C. E. M. D., Oriot, P., Philips, J., Vandenbroucke, M., Crenier, L., Nobels, F. R. E., Mathieu, C., & the Belgian Group of Experts IQED (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70049 · Cited by 2
Mathiesen, D. S., Hansen, J. V., Høck, A., Nielsen, C. K., Pedersen, M. G., Kristensen, P. L., Andersen, H. U., Aarestrup, M. L., Forman, J. L., Bagger, J. I., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70139 · Cited by 2
Cardiac Biomarkers, Intensive Lifestyle Intervention, and Heart Failure Subtypes in Diabetes
Chunawala, Z. S., Patel, K. V., Garcia, K. R., Segar, M. W., Verma, S., Bayés‐Genís, A., Pop‐Busui, R., Bhatt, D. L., Januzzi, J. L., Butler, J., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102726 · Cited by 2
Lan, N. S. R., Ryan, C. D., Rudén, A., Glasby, J. R. K., Nanayakkara, N., Elghattis, Y., Brazionis, L., Huang, M., Lum, S., Januszewski, A. S., et al. (2025) · Internal Medicine Journal · doi:10.1111/imj.70276 · Cited by 3
Li, J., Li, J., Ke, C., Sun, Y., Tan, X. W., Chen, Y., Lu, Y., & Wang, N. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000004348 · Cited by 2
Georeli, E., Sotiriou, G., Chainoglou, A., Galli‐Τsinopoulou, A., Stabouli, S., & Christoforidis, A. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113132 · Cited by 2
Ternhamar, T., Johansen, M. Ø., Nordestgaard, B. G., & Afzal, S. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag085 · Cited by 2
Janssen, J. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052150 · Cited by 2
Cardiovascular risk equations in type 1 diabetes: from generic models to personalized prediction
Serés‐Noriega, T., Lafarga, I. A., Perea, V., Viñals, C., & Amor, A. J. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2642404 · Cited by 2
Keisala, E., Kauppala, T., Vanhamäki, S., Haapakoski, J., Laatikainen, T., & Metso, S. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109312 · Cited by 2
Wyss, F. S., Ullauri, V. E., Lara-Terán, J. J., Arteaga-Arellano, A., Martín, C. G., López-Santi, R., Pérez, G., Madrigal, C. A., Ger, M., Piskorz, D. L., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02157-5 · Cited by 2
Okafor, I. N., & Chisom, C. E. (2026) · International Journal of Latest Technology in Engineering Management & Applied Science · doi:10.51583/ijltemas.2026.150500275 · Cited by 2
Diabetes and Cardiovascular Disease in Women: Current Challenges and New Hope
Koutroumpakis, E., & Aguilar, D. A. (2020) · Texas Heart Institute Journal · doi:10.14503/thij-19-7068 · Cited by 2
Hata, S., Ushigome, E., Yoshimura, T., Takegami, M., Kitagawa, N., Tanaka, T., Hasegawa, G., Ohnishi, M., Tsunoda, S., Yokota, I., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003273 · Cited by 2
She, Y., & Liu, Z. (2022) · Cellular and Molecular Biology · doi:10.14715/cmb/2022.68.3.25 · Cited by 2
Heinrich, N. S., Kriegbaum, M., Grand, M. K., Lind, B., Andersen, C. L., & Persson, F. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.10.006 · Cited by 2
Managing type 1 diabetes in children and young people: challenges and solutions
Wilson, V. (2023) · Nursing Children and Young People · doi:10.7748/ncyp.2023.e1465 · Cited by 2
Rajapaksa, R., Davis, W. A., & Davis, T. M. E. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003501 · Cited by 2
Rautio, E., Gadler, F., Guðbjörnsdóttir, S., Franzén, S., Rydén, L., Savarese, G., Svensson, J., & Mellbin, L. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02084-z · Cited by 2
Self-citationEsparham, A., Roohi, S., Moghaddam, A. A., Moghadam, H. A., Shoar, S., & Khorgami, Z. (2024) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2024.04.010 · Cited by 2
Shang, Y., Wang, S., Wei, C., & Xie, H. (2024) · Journal of Applied Gerontology · doi:10.1177/07334648241241392 · Cited by 2
Nath, N. D., & Odoi, A. (2024) · PeerJ · doi:10.7717/peerj.17408 · Cited by 2
Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers
Moura, F. A., Kamanu, F., Wiviott, S. D., Giugliano, R. P., Udler, M. S., Florez, J. C., Ellinor, P. T., Sabatine, M. S., Ruff, C. T., & Marston, N. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16123 · Cited by 2
Duan, X., Wei, Y., Ge, Y., Bo, Y., Wang, X., & Zhu, Y. (2025) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2024-222775 · Cited by 2
Advances in Type II Diabetes Prediction: A Comprehensive Review of Machine Learning Techniques
Kushwah, V. S., Krishnan, S. B., Upreti, K., Kumar, M., Kshirsagar, P. R., & Singh, V. K. (2025) · International Conference on Intelligent Control, Computing and Communications (IC3) · doi:10.1109/ic363308.2025.10956963 · Cited by 2
Impact of Melatonin on Brain Metabolism in Diabetes: A Narrative Review
Nwaji, A. R., Bisong, S. A., Antai, A. B., Okakpu, C. M., Okechukwu, M. P., Igwe, E. O., Okafor, C., Odoh, P. C., Chukwu, M. C., Esinulo, J. I., et al. (2025) · Natural Product Communications · doi:10.1177/1934578x251340772 · Cited by 2
Chen, Y., Fang, C., Zhao, J., Jiang, S., Xu, X., Cui, L., Zhao, R., Ma, X., Lin, T., Yu, H., et al. (2025) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeaf219 · Cited by 2
Petermann-Rocha, F. E., Garrido-Méndez, Á., Díaz-Martínez, X., Leiva, A. M., Martínez, M., Poblete-Valderrama, F., Salas, C., Cristi‐Montero, C., & Celis-Morales, C. A. (2018) · Revista médica de Chile · doi:10.4067/s0034-98872018000400433 · Cited by 2
Primary prevention of cardiovascular diseases in diabetes mellitus: 2020 strategy
Novikov, V. I., & Novikov, K. Y. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-4-42-49 · Cited by 2
Haq, M. E. U., Akash, M. S. H., Rehman, K., & Khurshid, M. (2020) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2019-0318 · Cited by 2
Li, J., Ren, Y., Siyuan, L., & Li, J. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s305831 · Cited by 2
Miętkiewska-Dolecka, M., & Uruska, A. A. (2021) · Journal of Medical Science · doi:10.20883/medical.e531 · Cited by 2
Smith, A., Kennedy, C., Clarke, S., & Barry, M. G. (2021) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2021.100038 · Cited by 2
Chung, S. M., Lee, K., Han, E., Seo, H.-A., Jeon, E. J., Kim, H. S., & Yoon, J. S. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1515 · Cited by 2
Inpatient Mortality in People With Type 2 Diabetes: A Cross-sectional Study
Carrondo, M. C., & Moita, J. J. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0049 · Cited by 2
Dantan, É., Pailler, M., Ragot, S., Gand, E., Trochu, J., Cariou, B., Saulnier, P., & Hadjadj, S. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110152 · Cited by 2
SmartLab 2.0 in cardiovascular prevention of atherogenic dyslipidemia
Toribio, R. G., Velilla, T. A., Porillo, C. M., Rico, M. Á., Quesada, M. M., & León‐Justel, A. (2023) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2023.05.009 · Cited by 2
Jurado, A. L., López‐Siguero, J. P., Gómez‐Perea, A., Jiménez, A. B. A., Becerra‐Paz, I., Ceballos, L. T., Ponce, C. C., Hinojosa, J. M. J., Morcillo, S., & Gea, I. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216951 · Cited by 2
N-terminal Pro-B-Type Natriuretic Peptide and Risk for Diabetes Mellitus and Metabolic Syndrome
Nicoli, C. D., Long, D. L., Plante, T. B., Judd, S. E., McClure, L. A., Carson, A. P., & Cushman, M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae301 · Cited by 2
Mortality patterns in Dutch diabetes outpatients
Bak, J. C. G., de Vries, S. A. G., Serné, E. H., Groenwold, R. H. H., de Valk, H. W., Mul, D., Sas, T., Bizino, M. B., Nieuwdorp, M., Kramer, M. H. H., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15750 · Cited by 2
Antidiabetic medications and mortality reduction: a shift from surrogate to clinical endpoints
Hasan, F., & Hasan, B. (2017) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018817737955 · Cited by 2
A LEADER in the management of type 2 diabetes and cardiorenal disease
Verma, S., Leiter, L. A., Latter, D. A., & Bhatt, D. L. (2019) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.03.134 · Cited by 2
Stefan, N. (2020) · Diabetes Mellitus · doi:10.14341/dm10376 · Cited by 2
Antiphospholipid antibodies in patients with dysglycaemia: A neglected cardiovascular risk factor?
Ferrannini, G., Svenungsson, E., Kjellström, B., Elvin, K., Grosso, G., Näsman, P., Rydén, L., & Norhammar, A. (2020) · Diabetes and Vascular Disease Research · doi:10.1177/1479164120922123 · Cited by 2
Liu, M., Zhang, H., Song, H., Cheng, N., Wu, Y., & Wang, R. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001421 · Cited by 2
Rationale for glycemic control to improve cardiovascular outcome: Lessons from east and west
Bloomgarden, Z. T., & Chan, J. C. N. (2021) · Journal of Diabetes · doi:10.1111/1753-0407.13204 · Cited by 2
Stocker, R., Shaw, J., Taylor, G., Witham, M. D., & West, D. J. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-048932 · Cited by 2
Diabetic women: Inpatient mortality risk before SARS-CoV-2
Carrondo, M. C. (2022) · Obesity Medicine · doi:10.1016/j.obmed.2022.100413 · Cited by 2
Wesley, J. D., Pagni, P. P., Bergholdt, R., Kreiner, F. F., & von Herrath, M. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000742 · Cited by 2
Qiao, T., Zhao, H., Luo, T., Wang, D., Mu, K., Aimudula, A., Pei, H., Zhang, G., & Dai, J. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/2802828 · Cited by 2
RetractedAltered Metabolome of Amino Acids Species: A Source of Signature Early Biomarkers of T2DM
Czajkowska, A., Hameed, A., Galli, M., Ijaz, M. U., Kretowski, A. J., & Ciborowski, M. (2022) · Biomarkers in disease · doi:10.1007/978-3-031-08014-2_5 · Cited by 2
Sun, J., Xu, J., Liu, Y., Xu, X., Zhang, S., Hao, Y., Lin, Y., Han, Y., Li, F., & Yuan, H. S. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1022861 · Cited by 2
Mitrea, A., Vladu, I. M., Rosu, M. M., Clenciu, D., Moța, E., & Moța, M. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002510 · Cited by 2
Conde-Carmona, I., García-Medina, S., Jiménez-Vargas, J. M., Muñoz, A. M., & Lee, S. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.08.015 · Cited by 2
Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Pietraszek, A. (2020) · Current Drug Safety · doi:10.2174/1574886315666200902154736 · Cited by 2
Hitchen, S. A., Lan, N. S. R., Fegan, P. G., & Yeap, B. B. (2020) · Internal Medicine Journal · doi:10.1111/imj.15055 · Cited by 2
Kryvoviaz, Y. O. (2020) · Biomedical and Biosocial Anthropology · doi:10.31393/bba38-2020-09 · Cited by 2
Reflections on Diabetes Care at the End of the Second Decade of the 21st Century
Garg, S. K. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0014 · Cited by 2
Diabetes and Covid‐19: An interplay difficult to dissect
Napoli, R. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3387 · Cited by 2
Muriel, R. A. S. (2022) · Gredos (University of Salamanca) · doi:10.14201/gredos.149564 · Cited by 2
Asadi, Z., Ghazizadeh, H., Yaghooti, M., Bijari, M., Khedmatgozar, H., Dabagh, A. E., Mohammadi, M. A., Fazl, M. R., Kadkhoda-Ahmadi, S., Moazedi, S., et al. (2020) · doi:10.21203/rs.3.rs-35931/v1 · Cited by 2
Promoting Health and Improving Quality of Life in Diabetes
Martyn-Nemeth, P. A., & Hayman, L. L. (2021) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000000842 · Cited by 1
Clinical Care of Lipids in People with Type 1 Diabetes
Lan, N. S. R., Jenkins, A. J., & Fegan, P. G. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_28 · Cited by 2
Devy, Jansen, & Yani, H. (2024) · International Journal of Public Health Excellence (IJPHE) · doi:10.55299/ijphe.v3i2.752 · Cited by 1
Metadata
- Authors
- Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S.
- Affiliations
- University of Glasgow (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-04-13
- Volume
- 376
- Issue
- 15
- Pages
- 1407-1418
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2606281213
- Cited by
- 1,389
- References
- 37
- Citations by year
- 2026: 100 · 2025: 144 · 2024: 163 · 2023: 149 · 2022: 184 · 2021: 176 · 2020: 196 · 2019: 140 · 2018: 95 · 2017: 39
- FWCI
- 101.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, type 2 diabetes, cardiovascular disease, mortality, coronary artery disease, cardiovascular hospitalization, Sweden, diabetes registry, standardized incidence rate
- MeSH terms
- Adolescent, Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, Hospitalization, Humans, Male, Middle Aged, Mortality, Registries, Risk Factors, Sweden, Incidence, Proportional Hazards Models, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
